IN8BIO, Inc. SEC filings INAB

IN8BIO, Inc. has 410 filings in SEC EDGAR's recent list, going back to May 22, 2018. Its latest annual report, Form ARS, was filed on Mar 26, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 6, 2026 (results of operations). The company's fiscal year ends on December 31.

Form Description Filed Period
DEFA14A Additional proxy material Mar 26, 2026 —
DEF 14A Proxy statement Mar 26, 2026 May 7, 2026
DEFA14A Additional proxy material Mar 17, 2025 —
DEF 14A Proxy statement Mar 17, 2025 May 8, 2025
PRE 14A Preliminary proxy statement Mar 5, 2025 May 8, 2025
DEFA14A Additional proxy material Apr 26, 2024 —
DEF 14A Proxy statement Apr 26, 2024 Jun 12, 2024
DEFA14A Additional proxy material May 1, 2023 —
DEF 14A Proxy statement May 1, 2023 Jun 15, 2023
DEFA14A Additional proxy material Apr 22, 2022 —
DEF 14A Proxy statement Apr 22, 2022 Jun 1, 2022

Showing 11 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
INAB (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
New York, NY
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1740279
Former names
Incysus Therapeutics, Inc. (until Sep 20, 2018)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.